IOPIDINE
LOE Approachingapraclonidine hydrochloride ophthalmic solution
NDAOPHTHALMICSOLUTION/DROPS
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
IOPIDINE (apraclonidine hydrochloride ophthalmic solution) is apraclonidine is a relatively selective, alpha adrenergic agonist and does not have significant membrane stabilizing (local anesthetic) activity. First approved in 1987.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IOPIDINE (apraclonidine HCl ophthalmic solution) is a selective alpha-adrenergic agonist administered as eye drops that reduces intraocular pressure (IOP) by decreasing aqueous humor formation. It is primarily used to prevent or control acute IOP elevation following laser eye surgery procedures such as argon trabeculoplasty, iridotomy, and Nd:YAG capsulotomy. The drug demonstrates onset within one hour with peak effect at 3–5 hours post-instillation.
$0.105MPart D
LOE ApproachingDeclining
Minimal commercial activity with only $105K in annual Part D spending signals a niche, low-volume product with limited career expansion opportunities on the brand team.
Mechanism of Action
Apraclonidine is a relatively selective, alpha adrenergic agonist and does not have significant membrane stabilizing (local anesthetic) activity. When instilled into the eye, IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) has the action of reducing intraocular pressure (IOP).…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.